Kallyope, based in the Alexandria Center for Life Science in New York City, secured $112 million in a Series C financing round that will be used to advance the company’s gut-brain axis field-focused programs into clinical trials.

The Indian government banned the export of hydroxychloroquine and formulations made from the medication, as experts test the efficacy of the drug in helping treat patients infected with COVID-19.

As the world tries to limit the spread of the novel coronavirus that causes COVID-19, there is some hope that warmer weather will cause the virus to dwindle, like what happens with seasonal influenza. Though research indicates that COVID-19 could be seasonal, returning in the fall.

Gaithersburg, Maryland-based Novavax announced positive topline data from the company’s pivotal Phase III clinical trial of the seasonal flu vaccine NanoFlu.

Bay Area-based CytomX and Astellas forged a strategic relationship worth up to more than $1.6 billion to discover and develop novel T-cell engaging bispecific antibodies targeting CD3 and tumor cell surface antigens for the treatment of cancer.

New York will launch a clinical trial using blood plasma from patients who have recovered from COVID-19, the disease caused by the novel coronavirus.

A key modeling study from Singapore has found that putting multiple social lockdowns in place – including school closures – will have the biggest impact on curbing COVID-19, the pandemic disease caused by the new coronavirus.

Gilead Sciences has been overwhelmed with requests for remdesivir to treat cases of COVID-19, the disease caused by the novel coronavirus.

A lot of attention shifted to the malaria drug hydroxychloroquine for treatment of COVID-19, the disease caused by the novel coronavirus.

U.S. drugmaker Bristol Myers Squibb Co. will put off beginning new clinical trials for at least three weeks because of the impact of the fast-spreading coronavirus pandemic.